UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Is Half-Life a Clinically Relevant Measure for Extended-Release Drugs? Data Comparing Immediate- and Extended-Release Topiramate (USL255; Qudexy™ XR) (P1.249)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Comparison of the Pharmacokinetics of USL255, an Extended-Release Topiramate, When Sprinkled Onto Soft Food or Swallowed Intact (P3.258)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

USL255, Extended-Release Topiramate, Displays an Improved Pharmacokinetic Profile With Reduced Adverse Events Compared With Immediate-Release Topiramate (P3.265)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

The Application of Half-Life in Clinical Decision Making: Comparison of the Pharmacokinetics of Extended-Release Topiramate (USL255) and Immediate-Release Topiramate

Epilepsy research, 2017-01, Vol.129, p.26-32

2017

Volltextzugriff (PDF)

Investigations of USL255, Qudexy™ XR (Topiramate) Extended-Release Capsules, Sprinkled onto Soft Food or Delivered via Enteral Feeding Tubes (P1.248)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Use of Investigator Training to Improve Seizure Classification in PREVAIL: A Phase 3, Global Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Adults With Partial-Onset Seizures (P3.280)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Impact of Delayed-Dose Administration of USL255, an Extended-Release Topiramate Formulation (P3.257)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Long-Term Open-Label Extension (OLE) Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Patients With Partial Onset Seizures: Interim Analysis From PREVAIL OLE (P3.284)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Adverse Event Profile of USL255 in Patients with Refractory Partial-Onset Seizures: The PREVAIL Study (P3.262)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Long-Term Efficacy, Safety, and Impact on Quality of Life of USL255, Qudexy™ XR (Topiramate) Extended-Release Capsules: PREVAIL OLE (P1.247)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes

Epilepsy & behavior, 2016-04, Vol.57 (Pt A), p.105-110

2016

Volltextzugriff (PDF)

Early Onset of Efficacy and Safety Outcomes with USL255 Treatment: The PREVAIL Study (P3.264)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Comparison of Adverse Effects of USL255 and Commonly Prescribed AEDs: Assessment of Relative Risk (P3.266)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: Randomized phase III study

Epilepsia (Copenhagen), 2014-07, Vol.55 (7), p.1077-1087

2014

Volltextzugriff (PDF)

Efficacy and safety of USL255 (Qudexy™ XR; extended-release topiramate) for adjunctive treatment of partial-onset seizures: The PREVAIL study

Epilepsy & behavior, 2015-05, Vol.46, p.51-51

2015

Volltextzugriff (PDF)

Efficacy, Safety, and Impact on Quality of Life of USL255 in Patients with Refractory Partial-Onset Seizures: The PREVAIL Study (P3.261)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Efficacy of USL255 Across Partial-Onset Seizure Types and Refractory Patient Status: Subgroup Analyses From the PREVAIL Study (P3.263)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures

Epilepsy & behavior, 2016-06, Vol.59, p.13-20

2016

Volltextzugriff (PDF)

Once‐daily USL 255 as adjunctive treatment of partial‐onset seizures: Randomized phase III study

Epilepsia (Copenhagen), 2014-07, Vol.55 (7), p.1077-1087

2014

Volltextzugriff (PDF)

Efficacy of once-daily extended-release topiramate (USL255): A subgroup analysis based on the level of treatment resistance

Epilepsy & behavior, 2014-12, Vol.41, p.136-139

2014

Volltextzugriff (PDF)

Best practices for BPM deployments

AIIM E - Doc Magazine, 2003-05, Vol.17 (3), p.17

2003

Volltextzugriff (PDF)

E-billing shifts focus to B2B

Collections & Credit Risk, 2001-11, Vol.6 (11), p.24

2001

Volltextzugriff (PDF)

Debating Leaderless Management: Can Employees Do Without Leaders?

1, 2022

Volltextzugriff (PDF)

Characterization and Correction of Geometric Distortions in 814 Diffusion Weighted Images

PloS one, 2016-03, Vol.11 (3), p.e0152472-e0152472

2016

Volltextzugriff (PDF)

A validation study of the CarerQol instrument in informal caregivers of people with dementia from eight European countries

Quality of life research, 2021-02, Vol.30 (2), p.577-588

2021

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(121)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Is Half-Life a Clinically Relevant Measure for Extended-Release Drugs? Data Comparing Immediate- and Extended-Release Topiramate (USL255; Qudexy™ XR) (P1.249)

Comparison of the Pharmacokinetics of USL255, an Extended-Release Topiramate, When Sprinkled Onto Soft Food or Swallowed Intact (P3.258)

USL255, Extended-Release Topiramate, Displays an Improved Pharmacokinetic Profile With Reduced Adverse Events Compared With Immediate-Release Topiramate (P3.265)

The Application of Half-Life in Clinical Decision Making: Comparison of the Pharmacokinetics of Extended-Release Topiramate (USL255) and Immediate-Release Topiramate

Investigations of USL255, Qudexy™ XR (Topiramate) Extended-Release Capsules, Sprinkled onto Soft Food or Delivered via Enteral Feeding Tubes (P1.248)

Use of Investigator Training to Improve Seizure Classification in PREVAIL: A Phase 3, Global Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Adults With Partial-Onset Seizures (P3.280)

Impact of Delayed-Dose Administration of USL255, an Extended-Release Topiramate Formulation (P3.257)

Long-Term Open-Label Extension (OLE) Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Patients With Partial Onset Seizures: Interim Analysis From PREVAIL OLE (P3.284)

Adverse Event Profile of USL255 in Patients with Refractory Partial-Onset Seizures: The PREVAIL Study (P3.262)

Long-Term Efficacy, Safety, and Impact on Quality of Life of USL255, Qudexy™ XR (Topiramate) Extended-Release Capsules: PREVAIL OLE (P1.247)

Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes

Early Onset of Efficacy and Safety Outcomes with USL255 Treatment: The PREVAIL Study (P3.264)

Comparison of Adverse Effects of USL255 and Commonly Prescribed AEDs: Assessment of Relative Risk (P3.266)

Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: Randomized phase III study

Efficacy and safety of USL255 (Qudexy™ XR; extended-release topiramate) for adjunctive treatment of partial-onset seizures: The PREVAIL study

Efficacy, Safety, and Impact on Quality of Life of USL255 in Patients with Refractory Partial-Onset Seizures: The PREVAIL Study (P3.261)

Efficacy of USL255 Across Partial-Onset Seizure Types and Refractory Patient Status: Subgroup Analyses From the PREVAIL Study (P3.263)

Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures

Once‐daily USL 255 as adjunctive treatment of partial‐onset seizures: Randomized phase III study

Efficacy of once-daily extended-release topiramate (USL255): A subgroup analysis based on the level of treatment resistance

Best practices for BPM deployments

E-billing shifts focus to B2B

Debating Leaderless Management: Can Employees Do Without Leaders?

Characterization and Correction of Geometric Distortions in 814 Diffusion Weighted Images

A validation study of the CarerQol instrument in informal caregivers of people with dementia from eight European countries

Suchergebnisse filtern